Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke (CER)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01556854|
Recruitment Status : Unknown
Verified March 2012 by yongjun wang, Ministry of Science and Technology of the People´s Republic of China.
Recruitment status was: Recruiting
First Posted : March 16, 2012
Last Update Posted : March 16, 2012
The primary objective of this study is to compare effectiveness of five different neuroprotectants, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
The secondary objectives of the study are as follows:
- To compare safety of five different neuroprotectents, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
- To compare cost-effectiveness of five different neuroprotectents, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
|Condition or disease|
|Acute Ischemic Stroke|
Study Population:The study population will consist of consenting patients who are on neuroprotectant injection for the treatment of acute IS during hospitalization. Hospitals may contribute differing numbers of patients to the total sample size. Primary analyses will be conducted on the total sample size only.
Assessment of Outcomes:The outcome measures in this study include effectiveness, safety and cost measures.
|Study Type :||Observational|
|Estimated Enrollment :||20000 participants|
|Official Title:||Comparative Effectiveness of Different Neuroprotectants Among Patients With Acute Ischemic Stroke in Clinical Practice|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||November 2013|
|Estimated Study Completion Date :||June 2014|
- Effectiveness Outcome Measures [ Time Frame: 3 years ]
- The severity of neurological impairment evaluated by the NIHSS • Disability by mRS
- All cause mortality
- In-hospital recurrence and recurrence at 3 month post discharge
- In-hospital complications
- Cognitive disorder evaluated by MMSE
- Quality of Life evaluated by EQ5D
- Safety Outcome Measures [ Time Frame: 3 years ]
- prolonged inpatient hospitalization
- a life-threatening experience (that is, immediate risk of dying)
- persistent or significant disability/incapacity
- or is considered significant by the physician for any other reason.
- Cost-effectiveness Outcome Measures [ Time Frame: 2011.7-2014.6 ]
- Medical cost at discharge
- Drug cost at discharge
- Neuroprotectents cost at discharge
- Administration cost at discharge
- Medical cost at 3 month post discharge
- Drug cost at 3 month post discharge
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01556854
|Beijing, Beijing, China, 100050|
|Contact: Yilong Wang, Doctor 00861067098222 yilong528@Gmail.com|